slide 1

Back to the List of the Granted Patents                                                Click here to download AP2072 PDF

(11)    Patent No :    AP 2072   
(21)    Application No :    AP/P/2001/002365   
(22)    Filing Date :    20.12.2001   
(24)    Date of Grant &    10.12.2009   
           
(45)    Publication :

(30)  Priority Data       
(33) Country    (31) Number    (32) Date
US    60/259,927    05.01.2001

(84)    Designated State
BW    GM    GH    KE    LS   MW  MZ   SL   SD
SZ    T Z    UG    ZM    ZW
 
(73) Applicant(s)

PFIZER INC., 235 East 42nd Street , New York, New York 10017,
United States of America

AMGEN FREMONT INC., 6701 Kaiser Drive, Fremont, California 94555,

United States of America

(72) Inventors

COHEN Bruce D, United States of America

BEEBE Jean, United States of America

MILLER Penelope E, United States of America

et al

(74) Representative

FISHER CORMACK & BOTHA
 

(51)  International  Classification   A61K    67/027 (2006.01)    A61K 39/395 (2006.01)
A61K    45/00 (2006.01)   

(54)    Title

Antibodies to insulin-like growth factor I receptor

(57)    Abstract

The present invention relates to antibodies and antigen -binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion protein. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

(56)    Documents Cited :    KALIMAN P. et al (1992)    LI S -L et al: Cancer Immunology and Immunotherapy, Berlin, DE,

Vol.49, 4/5, 07.2000, pp243-52    XIONG L et al  (1992)    DRICU A et al (1999)

Newsletter

Join our newsletter for CIPIT news through subscriptions!

SEND

Social Media

    

Contact Us

TEL : (254) 703 034 612